OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
The past two decades have witnessed a revolution in rheumatoid arthritis (RA) outcomes, with remission now a realistic and achievable target for many patients. However, this heralds a new dilemma increasingly encountered in routine clinical practice: how best to manage expensive and potentially toxic immunosuppressive therapy in such individuals?
I will present our clinical trial data to support a composite biomarker capable of predicting drug-free remission in established RA. The concept of drug-free remission will also be explored from a patient perspective, together with ongoing and future avenues of research to better understand the pathoimmunological processes underpinning RA flare.
